Thalidomide | hsa00480 | Glutathione metabolism | 3.29E-04 | 4 | Q9UJ14, Q16772, P09211, P30041 | GGTL3, GSTA3, GSTP1, PRDX6 | More | |
Thalidomide | hsa00531 | Glycosaminoglycan degradation | 1.05E-03 | 2 | P15586, P34059 | GNS, GALNS | More | |
Thalidomide | hsa00532 | Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 3.30E-02 | 1 | Q9Y2C2 | UST | More | |
Thalidomide | hsa00562 | Inositol phosphate metabolism | 4.28E-02 | 2 | Q14642, P19174 | INPP5A, PLCG1 | More | |
Thalidomide | hsa00564 | Glycerophospholipid metabolism | 2.62E-02 | 2 | P23743, Q3LIE5 | DGKA, ADPRM | More | |
Thalidomide | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.46E-03 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | |
Thalidomide | hsa00982 | Drug metabolism - cytochrome P450 | 1.06E-02 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | |
Thalidomide | hsa00983 | Drug metabolism - other enzymes | 1.32E-04 | 5 | P04183, P32320, P05164, Q16772, P09211 | TK1, CDA, MPO, GSTA3, GSTP1 | More | |
Thalidomide | hsa01100 | Metabolic pathways | 8.43E-03 | 11 | P35790, Q16772, P09211, Q9UJ14, P30041, P40926, Q7KZN9, P15121, Q9UHK6, Q86VZ5, Q9BQB6 | CHKA, GSTA3, GSTP1, GGTL3, PRDX6, MDH2, COX15, AKR1B1, AMACR, SGMS1, VKORC1 | More | |
Thalidomide | hsa01522 | Endocrine resistance | 4.07E-04 | 5 | P14780, P22694, Q9UM47, P10415, Q13323 | MMP9, PRKACB, NOTCH3, BCL2, BIK | More | |
Thalidomide | hsa01524 | Platinum drug resistance | 4.44E-02 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | |
Thalidomide | hsa03050 | Proteasome | 4.83E-02 | 1 | P55036 | PSMD4 | More | |
Thalidomide | hsa03060 | Protein export | 3.56E-02 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | |
Thalidomide | hsa04012 | ErbB signaling pathway | 4.28E-02 | 2 | Q13191, P19174 | CBLB, PLCG1 | More | |
Thalidomide | hsa04020 | Calcium signaling pathway | 7.93E-03 | 6 | Q08828, Q13557, P61073, P0DP24, P05141, P51828 | ADCY1, CAMK2D, CXCR4, CALM2, SLC25A5, ADCY7 | More | |
Thalidomide | hsa04022 | cGMP-PKG signaling pathway | 1.87E-02 | 6 | Q99941, P18848, Q08828, P51828, P05141, P0DP24 | CREBL1, ATF4, ADCY1, ADCY7, SLC25A5, CALM2 | More | |
Thalidomide | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 1.91E-02 | 3 | Q8NHW4, P61073, Q13651 | CCL4L2, CXCR4, IL10RA | More | |
Thalidomide | hsa04064 | NF-kappa B signaling pathway | 1.47E-02 | 4 | P01584, P63279, Q8NHW4, Q9NQC7 | IL1B, UBE2I, CCL4L2, CYLD | More | |
Thalidomide | hsa04071 | Sphingolipid signaling pathway | 1.70E-03 | 5 | Q9H228, P01375, Q13362, Q9BX95, P10415 | EDG8, TNF, PPP2R5C, SGPP1, BCL2 | More | |
Thalidomide | hsa04114 | Oocyte meiosis | 4.36E-02 | 5 | Q13557, P0DP24, Q08828, P51828, P27348 | CAMK2D, CALM2, ADCY1, ADCY7, YWHAQ | More | |
Thalidomide | hsa04137 | Mitophagy - animal | 3.55E-04 | 4 | Q96CV9, Q9H1Y0, P18848, O43524 | OPTN, ATG5, ATF4, FOXO3 | More | |
Thalidomide | hsa04141 | Protein processing in endoplasmic reticulum | 3.68E-02 | 3 | P60604, P08238, Q9H173 | UBE2G2, HSP90AB1, SIL1 | More | |
Thalidomide | hsa04142 | Lysosome | 1.67E-03 | 4 | P43234, P15586, P34059, P49281 | CTSO, GNS, GALNS, SLC11A2 | More | |
Thalidomide | hsa04146 | Peroxisome | 4.38E-03 | 4 | O43933, O96011, P56589, P33121 | PEX1, PEX11B, PEX3, ACSL1 | More | |
Thalidomide | hsa04210 | Apoptosis | 1.43E-02 | 4 | P04637, P24522, P43234, P63261 | TP53, GADD45A, CTSO, ACTG1 | More | |
Thalidomide | hsa04211 | Longevity regulating pathway | 4.98E-02 | 4 | Q08828, P51828, Q99941, P18848 | ADCY1, ADCY7, CREBL1, ATF4 | More | |
Thalidomide | hsa04213 | Longevity regulating pathway - multiple species | 8.73E-03 | 3 | Q9Y4H2, P11142, Q13547 | IRS2, HSPA8, HDAC1 | More | |
Thalidomide | hsa04216 | Ferroptosis | 1.45E-02 | 2 | P04637, P49281 | TP53, SLC11A2 | More | |
Thalidomide | hsa04217 | Necroptosis | 5.85E-03 | 7 | P23458, Q9NQC7, P05141, P01584, P0C0S5, Q13557, Q9H444 | JAK1, CYLD, SLC25A5, IL1B, H2AFZ, CAMK2D, CHMP4B | More | |
Thalidomide | hsa04261 | Adrenergic signaling in cardiomyocytes | 1.44E-02 | 6 | Q08828, P51828, Q99941, P18848, P0DP24, Q13557 | ADCY1, ADCY7, CREBL1, ATF4, CALM2, CAMK2D | More | |
Thalidomide | hsa04340 | Hedgehog signaling pathway | 2.62E-02 | 2 | O43791, P30279 | SPOP, CCND2 | More | |
Thalidomide | hsa04371 | Apelin signaling pathway | 2.77E-02 | 3 | P62873, Q13370, Q9UM47 | GNB1, PDE3B, NOTCH3 | More | |
Thalidomide | hsa04380 | Osteoclast differentiation | 4.98E-02 | 4 | Q9NQC7, Q9UQC2, P23458, P01584 | CYLD, GAB2, JAK1, IL1B | More | |
Thalidomide | hsa04612 | Antigen processing and presentation | 6.19E-03 | 8 | P48382, P26715, P26717, Q13241, O43908, P01732, P11142, P01375 | RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, HSPA8, TNF | More | |
Thalidomide | hsa04613 | Neutrophil extracellular trap formation | 1.32E-06 | 16 | P19174, P11215, O60603, P05164, P08246, Q9UM07, Q13547, Q6FI13, P62807, Q15080, P20160, P08311, P49913, O75015, P21730, P21462 | PLCG1, ITGAM, TLR2, MPO, ELA2, PADI4, HDAC1, H2AC18; H2AC19, HIST1H2BC, NCF4, AZU1, CTSG, CAMP, FCGR3B, C5AR1, FPR1 | More | |
Thalidomide | hsa04621 | NOD-like receptor signaling pathway | 2.14E-04 | 10 | Q9H1Y0, P43490, O00463, P10415, Q05823, P01375, P49913, P59665, P59666, P12838 | ATG5, PBEF1, TRAF5, BCL2, RNASEL, TNF, CAMP, DEFA1; DEFA1B, DEFA3, DEFA4 | More | |
Thalidomide | hsa04623 | Cytosolic DNA-sensing pathway | 1.20E-02 | 2 | P01584, Q8NHW4 | IL1B, CCL4L2 | More | |
Thalidomide | hsa04650 | Natural killer cell mediated cytotoxicity | 1.25E-02 | 8 | P01375, O60880, P20963, Q13241, P26718, O75015, P26717, P26715 | TNF, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC1 | More | |
Thalidomide | hsa04657 | IL-17 signaling pathway | 2.90E-03 | 4 | P25963, P08238, P04141, P06702 | NFKBIA, HSP90AB1, CSF2, S100A9 | More | |
Thalidomide | hsa04658 | Th1 and Th2 cell differentiation | 2.37E-02 | 3 | P25963, P42224, Q9UM47 | NFKBIA, STAT1, NOTCH3 | More | |
Thalidomide | hsa04659 | Th17 cell differentiation | 4.18E-02 | 3 | P25963, P42224, P08238 | NFKBIA, STAT1, HSP90AB1 | More | |
Thalidomide | hsa04713 | Circadian entrainment | 1.91E-02 | 4 | P0DP24, Q13557, Q08828, P51828 | CALM2, CAMK2D, ADCY1, ADCY7 | More | |
Thalidomide | hsa04720 | Long-term potentiation | 1.91E-02 | 4 | Q13557, P0DP24, P18848, Q08828 | CAMK2D, CALM2, ATF4, ADCY1 | More | |
Thalidomide | hsa04725 | Cholinergic synapse | 3.77E-02 | 4 | Q08828, P51828, P18848, Q13557 | ADCY1, ADCY7, ATF4, CAMK2D | More | |
Thalidomide | hsa04728 | Dopaminergic synapse | 2.67E-02 | 5 | Q99941, P18848, Q13557, P0DP24, O15516 | CREBL1, ATF4, CAMK2D, CALM2, CLOCK | More | |
Thalidomide | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.47E-03 | 5 | P01584, Q08828, P51828, Q13557, P0DP24 | IL1B, ADCY1, ADCY7, CAMK2D, CALM2 | More | |
Thalidomide | hsa04910 | Insulin signaling pathway | 1.67E-02 | 3 | Q14642, Q13191, Q9Y4H2 | INPP5A, CBLB, IRS2 | More | |
Thalidomide | hsa04911 | Insulin secretion | 7.16E-04 | 5 | Q08828, P51828, Q99941, P18848, Q13557 | ADCY1, ADCY7, CREBL1, ATF4, CAMK2D | More | |
Thalidomide | hsa04912 | GnRH signaling pathway | 6.99E-03 | 5 | Q08828, P51828, P18848, Q13557, P0DP24 | ADCY1, ADCY7, ATF4, CAMK2D, CALM2 | More | |
Thalidomide | hsa04916 | Melanogenesis | 7.61E-03 | 4 | Q13557, P0DP24, Q08828, P51828 | CAMK2D, CALM2, ADCY1, ADCY7 | More | |
Thalidomide | hsa04918 | Thyroid hormone synthesis | 4.47E-03 | 5 | Q08828, P51828, Q99941, P18848, P02768 | ADCY1, ADCY7, CREBL1, ATF4, ALB | More | |
Thalidomide | hsa04925 | Aldosterone synthesis and secretion | 5.21E-04 | 6 | Q99941, P18848, Q08828, P51828, P0DP24, Q13557 | CREBL1, ATF4, ADCY1, ADCY7, CALM2, CAMK2D | More | |
Thalidomide | hsa04927 | Cortisol synthesis and secretion | 4.16E-03 | 4 | Q99941, P18848, Q08828, P51828 | CREBL1, ATF4, ADCY1, ADCY7 | More | |
Thalidomide | hsa04928 | Parathyroid hormone synthesis, secretion and action | 3.77E-02 | 4 | Q08828, P51828, Q99941, P18848 | ADCY1, ADCY7, CREBL1, ATF4 | More | |
Thalidomide | hsa04932 | Non-alcoholic fatty liver disease | 3.45E-02 | 5 | P18848, O75460, P01584, P12074, O15239 | ATF4, ERN1, IL1B, COX6A1, NDUFA1 | More | |
Thalidomide | hsa04934 | Cushing syndrome | 2.60E-04 | 6 | Q99941, P18848, Q08828, P51828, O15169, Q13557 | CREBL1, ATF4, ADCY1, ADCY7, AXIN1, CAMK2D | More | |
Thalidomide | hsa04935 | Growth hormone synthesis, secretion and action | 4.98E-02 | 4 | Q08828, P51828, Q99941, P18848 | ADCY1, ADCY7, CREBL1, ATF4 | More | |
Thalidomide | hsa04970 | Salivary secretion | 3.54E-02 | 3 | Q08828, P51828, P0DP24 | ADCY1, ADCY7, CALM2 | More | |
Thalidomide | hsa04971 | Gastric acid secretion | 7.16E-04 | 5 | Q08828, P51828, P15311, P0DP24, Q13557 | ADCY1, ADCY7, VIL2, CALM2, CAMK2D | More | |
Thalidomide | hsa05010 | Alzheimer disease | 3.73E-03 | 11 | O15239, P12074, Q00535, O75460, P0DP24, P01584, P18848, O15169, P05141, P28070, P43686 | NDUFA1, COX6A1, CDK5, ERN1, CALM2, IL1B, ATF4, AXIN1, SLC25A5, PSMB4, PSMC4 | More | |
Thalidomide | hsa05012 | Parkinson disease | 7.90E-03 | 9 | O15239, P12074, P05141, O75460, P18848, P28070, P43686, P0DP24, Q13557 | NDUFA1, COX6A1, SLC25A5, ERN1, ATF4, PSMB4, PSMC4, CALM2, CAMK2D | More | |
Thalidomide | hsa05016 | Huntington disease | 3.54E-02 | 8 | O15239, P12074, P24928, P62487, P05141, O75460, P28070, P43686 | NDUFA1, COX6A1, POLR2A, POLR2G, SLC25A5, ERN1, PSMB4, PSMC4 | More | |
Thalidomide | hsa05020 | Prion disease | 2.86E-02 | 9 | P01584, P46531, O15239, P12074, P18848, P05141, P28070, P43686, Q99941 | IL1B, NOTCH1, NDUFA1, COX6A1, ATF4, SLC25A5, PSMB4, PSMC4, CREBL1 | More | |
Thalidomide | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.74E-03 | 13 | O15239, P12074, Q8TEV9, O75460, P18848, P05141, Q00535, O15169, P01584, P0DP24, Q13557, P28070, P43686 | NDUFA1, COX6A1, SMCR8, ERN1, ATF4, SLC25A5, CDK5, AXIN1, IL1B, CALM2, CAMK2D, PSMB4, PSMC4 | More | |
Thalidomide | hsa05030 | Cocaine addiction | 3.54E-02 | 3 | Q00535, Q99941, P18848 | CDK5, CREBL1, ATF4 | More | |
Thalidomide | hsa05031 | Amphetamine addiction | 7.61E-03 | 4 | P0DP24, Q13557, Q99941, P18848 | CALM2, CAMK2D, CREBL1, ATF4 | More | |
Thalidomide | hsa05131 | Shigellosis | 3.32E-03 | 9 | P01375, O00463, Q04759, Q9UDY8, Q9H1Y0, P20810, O43524, P10415, Q96A32 | TNF, TRAF5, PRKCQ, MALT1, ATG5, CAST, FOXO3, BCL2, MYLPF | More | |
Thalidomide | hsa05134 | Legionellosis | 3.60E-03 | 3 | P11215, P11142, P19875 | ITGAM, HSPA8, CXCL2 | More | |
Thalidomide | hsa05140 | Leishmaniasis | 1.67E-02 | 3 | P42224, P25963, P29350 | STAT1, NFKBIA, PTPN6 | More | |
Thalidomide | hsa05144 | Malaria | 8.11E-05 | 5 | P60033, O60603, P01375, P35443, P26718 | CD81, TLR2, TNF, THBS4, KLRK1 | More | |
Thalidomide | hsa05150 | Staphylococcus aureus infection | 3.52E-06 | 7 | P21730, P21462, O75015, P59665, P59666, P12838, P49913 | C5AR1, FPR1, FCGR3B, DEFA1; DEFA1B, DEFA3, DEFA4, CAMP | More | |
Thalidomide | hsa05152 | Tuberculosis | 7.83E-04 | 7 | O75015, P48382, O60603, P01375, P10415, P49913, Q9UDY8 | FCGR3B, RFX5, TLR2, TNF, BCL2, CAMP, MALT1 | More | |
Thalidomide | hsa05163 | Human cytomegalovirus infection | 2.62E-04 | 10 | P0DP24, Q8NHW4, Q08828, P51828, P23458, P01584, P61073, Q13651, Q99941, P18848 | CALM2, CCL4L2, ADCY1, ADCY7, JAK1, IL1B, CXCR4, IL10RA, CREBL1, ATF4 | More | |
Thalidomide | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.63E-02 | 4 | P42224, P25963, P62873, P04141 | STAT1, NFKBIA, GNB1, CSF2 | More | |
Thalidomide | hsa05171 | Coronavirus disease - COVID-19 | 1.24E-02 | 4 | P25963, P42224, P46777, P04141 | NFKBIA, STAT1, RPL5, CSF2 | More | |
Thalidomide | hsa05200 | Pathways in cancer | 4.79E-02 | 6 | P08238, P42224, P25963, P20585, P62873, Q9UM47 | HSP90AB1, STAT1, NFKBIA, MSH3, GNB1, NOTCH3 | More | |
Thalidomide | hsa05203 | Viral carcinogenesis | 1.13E-03 | 6 | Q12933, P42229, P30279, Q13547, Q15283, P62807 | TRAF2, STAT5A, CCND2, HDAC1, RASA2, HIST1H2BC | More | |
Thalidomide | hsa05204 | Chemical carcinogenesis | 5.46E-03 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | |
Thalidomide | hsa05206 | MicroRNAs in cancer | 1.63E-02 | 4 | P30279, Q9Y4H2, Q13547, P19174 | CCND2, IRS2, HDAC1, PLCG1 | More | |
Thalidomide | hsa05211 | Renal cell carcinoma | 9.88E-03 | 2 | Q06124, Q99814 | PTPN11, EPAS1 | More | |
Thalidomide | hsa05212 | Pancreatic cancer | 3.28E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | |
Thalidomide | hsa05213 | Endometrial cancer | 3.28E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | |
Thalidomide | hsa05214 | Glioma | 3.28E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | |
Thalidomide | hsa05215 | Prostate cancer | 2.00E-02 | 3 | P25963, Q9NRA1, P08238 | NFKBIA, PDGFC, HSP90AB1 | More | |
Thalidomide | hsa05216 | Thyroid cancer | 1.45E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | |
Thalidomide | hsa05217 | Basal cell carcinoma | 2.60E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | |
Thalidomide | hsa05218 | Melanoma | 1.45E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | |
Thalidomide | hsa05220 | Chronic myeloid leukemia | 1.12E-02 | 3 | Q06124, P04637, P24522 | PTPN11, TP53, GADD45A | More | |
Thalidomide | hsa05223 | Non-small cell lung cancer | 4.01E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | |
Thalidomide | hsa05225 | Hepatocellular carcinoma | 4.54E-02 | 3 | P04637, P24522, P63261 | TP53, GADD45A, ACTG1 | More | |
Thalidomide | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 2.37E-02 | 3 | P25963, P29350, P42224 | NFKBIA, PTPN6, STAT1 | More | |